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Case Report
Introduction
Pleomorphic xanthoastrocytoma (PXA) is a rare glial tumour.
It typically occurs in young patients in the first three decades
of life, and has a superficial cortical location and a relatively
good prognosis for long-term survival. It was first described by
Kepes and colleagues in 1979.1 The predominant histological
features of PXA are cellular pleomorphism, giant cells,
abundant lipid droplets in the cytoplasm of the tumour cells,
and large amounts of reticulin fibres in the stroma. The tumour
is thought to arise from subpial astrocytes. This is supported
by immunoreactivity to glial fibrillary acidic protein (GFAP)
and the cellular investment by basal lamina.1–3 Our patient
showed features of PXA with anaplastic change.
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Case report
The patient, a 10-year-old Malay boy, presented with a
2-month history of headache and altered sensorium associated
with occasional nausea and vomiting. He had one episode of
seizure about 1 month prior to admission. There was no
history of trauma, fever, fainting or chronic ear discharge.
About 3 days prior to admission, he was unable to walk and
his father noticed that he had marked weakness of his right
upper and lower limbs. He was then brought to a secondary
referral centre, and subsequently referred to our University
Hospital for further management.
On examination, the patient was conscious and the Glasgow
Coma Score (GCS) was 12/15. His pupils were unequal with
Noor Azam Nasuha,1 Abd. Hamid Daud,1 Mazira Mohamad Ghazali,1 Abdul Aziz Mohamed Yusoff,1 Norafiza
Zainuddin,1 Jafri Malin Abdullah,1 Samarenda Singh Mutum,2 Biswa Mohan Biswal,3 Abdul Rahman Mohd Ariff,4
Sarina Sulong5 and Mohd. Nizam Isa,5 Departments of 1Neuroscience, 2Pathology, 3Radiotherapy and Nuclear Medicine,
4Radiology, and 5The Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia.
A case of pleomorphic xanthoastrocytoma in a 10-year-old Malay boy is reported. The patient presented with
headache and epilepsy. On computed tomography, a ring-enhancing low-density lesion was observed in the left
fronto-temporal area. During surgery, a cystic tumour containing serous fluid was found and almost totally
removed. Histologically, the tumour exhibited marked pleomorphism of oval and spindle-shaped cells intermixed
with uni- and multinucleated giant cells, and xanthomatous cells with foamy cytoplasm. The tumour displayed
pericellular reticulin and periodic acid-Schiff positive granules. Focally, six mitotic characters per 10 high-power
fields were seen, and necrosis was confined only to the inner lining of the cyst. Mutational analysis showed that
a frameshift mutation (a 4-bp deletion) in the p53 gene had occurred in codons 273 and 274 of exon 8. No
mutation was detected in the p16 gene. No allelic loss and/or loss of heterozygosity were observed on chromosome
10 using microsatellite marker D105532. The patient was treated with postoperative radiotherapy because of
histological anaplasia and the presence of residual tumour. The patient showed marked neurological recovery
after a follow-up period of 2 years. [Asian J Surg 2003;26(2):120–5]
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the right pupil 2 mm in diameter and reactive, and the
left pupil irregular in shape. His temperature was 37.4˚C,
pulse was 120 bpm and blood pressure was 120/70 mmHg.
Examination of the central nervous system revealed reduced
muscle power in the left upper and lower limbs (grade 4/5) and
bilateral papilloedema. Other systems were essentially normal.
The clinical impression at that point of time was a space-
occupying lesion in the left fronto-parietal region, with the
possibility of cerebral abscess.
Preliminary investigations showed a very high leukocyte
count of 30,400/μL with normal haemoglobin, platelet and
electrolyte levels. Computed tomography (CT) of the brain
showed a multiloculated, ring-enhancing low-density lesion
in the left fronto-temporal area associated with ipsilateral
oedema of the white matter, causing a shift of midline to the
right (Figure 1). The contralateral lateral ventricle was dilated,
with an associated periventricular area of low attenuation
concordant with high-pressure obstructive hydrocephalus.
These features, together with the high leukocyte count and
short history of the presenting illness, led us to suspect a left
brain abscess causing obstructive hydrocephalus. An
emergency left craniectomy, with the intention of removal of
the brain abscess and insertion of an intracranial pressure
(ICP) monitoring catheter to reduce intracranial pressure,
was performed. During craniectomy, straw-coloured
fluid was aspirated from the left fronto-parietal region, and
instead of an abscess, a fleshy tumour with necrosis was
seen. Because the surgical team was unprepared for removal
of a solid tumour, only a biopsy was done. The patient
was admitted to the intensive care unit (ICU) for ICP
monitoring and cerebral resuscitation for gross intraoperative
cerebral oedema.
Postoperatively, the patient developed persistently high
ICP and was managed with cerebrospinal fluid drainage and
thiopentone coma. A repeat CT scan of the brain revealed that
the previously seen multiloculated, ring-enhancing tumour in
the left fronto-temporal region was still present and was
associated with an acute intracerebral haemorrhage and
oedema causing subfalcine herniation. The basal cisterns were
completely absent.
The patient underwent another operation 3 days later to
remove the tumour. Intraoperatively, a well-demarcated
tumour was found measuring approximately 7 cm by 5 cm.
Incomplete excision of about 70 g of tumour tissue was
done due to technical difficulty. A left frontal lobectomy
was performed. Postoperatively, the patient developed
complications, which necessitated prolonged intubation and
tracheotomy.
The patient was then sent for radiotherapy in view of the
residual tumour and the high mitotic activity seen on
histopathological examination. A radiation dose of 60 Gy in
20 divided doses over 6 weeks was delivered in two phases,
using the shrinking field technique and a 6 MV linear
accelerator. At the end of radiotherapy, the patient showed
good neurological recovery. At the time of this report (2 years
post-radiotherapy), the patient was ambulating well, with
normal sphincter control.
Pathological examination
Histopathologically, the biopsy and resected specimens showed
similar findings of a dense rim of cellular tumour tissue with
oedematous cerebral white matter on the outer side and necrotic
tissue on the inside of the tumour. The predominant cells
displayed oval or spindled vesicular nuclei and moderate
fibrillary cytoplasm. These were intermixed with pleomorphic
single or multinucleated giant cells with hyperchromatic
nuclei and abundant eosinophilic glassy cytoplasm, and
xanthomatous cells with foamy cytoplasm. Prominent
spindling of cells arranged perivascularly in interlacing fascicles
was conspicuous in several foci. The tumour was widely positive
for pericellular reticulin (Figure 2). The blood vessels in the
Figure 1. Axial computed tomography brain scan showing a
lobulated ring-enhancing mass (arrow) in the left frontal lobe
compressing the ipsilateral lateral ventricle. The midline is shifted to
the right. The visible ventricles are dilated.
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Figure 2. Tumour photomicrographs showing A) closely packed,
pleomorphic, spindle cells with vesicular nuclei, cells with vacuolated
cytoplasm, and a giant cell exhibiting hyperchromatic peripheral
nucleus and abundant eosinophilic cytoplasm (hematoxylin & eosin
x 200); B) several pleomorphic giant cells with hyperchromatic
single or multilobed nuclei and abundant eosinophilic cytoplasm
(hematoxylin & eosin x 400); and C) delicate pericellular reticulin
and perivascular arrangement of tumour cells (Gordon and Sweet’s
reticulin x 200).
pseudopallisading of tumour cells were absent. The tumour
exhibited a high mitotic rate of six mitotic characters per
10 high-power fields. Pink hyaline periodic acid-Schiff
(PAS)-positive, diastase-resistant granules were seen both
intracellularly and in the stroma in some foci. The tumour
was moderately positive for GFAP and S-100 protein
immunohistochemical stains. At the interface of the tumour
with the cerebral cortex, the tumour displayed a well-defined
border and did not infiltrate into the oedematous white matter.
The overall histological findings were interpreted as those of
PXA, with features of malignancy. Electron microscopy studies
were not carried out.
Molecular analysis
A DNA sample from the patient’s brain tumour tissue was
extracted using a commercial extraction kit (Qiagen, Valencia,
CA, USA) for mutational analysis of the p53 and p16 genes. In
addition, loss of heterozygosity (LOH) analysis was performed
on the sample using the microsatellite marker D105532.
Mutational analysis
Polymerase chain reaction (PCR)-single strand conformational
polymorphism (PCR-SSCP) was performed on hot spot exons
5 to 8 of the patient’s p53 gene and exon 1 and 2 of the p16
gene. The analyses of the p53 and p16 genes were performed as
described by Sarkar et al,4 Isa et al5 and Orita et al.6 In the SSCP
analysis of p53, a mobility shift was detected on electrophoresis
(Figure 3). Further DNA sequencing analysis identified a
frameshift mutation localized at codons 273 to 274 in exon 8
(deletion of 4 bp, CTGG). No shifted band was detected on
mutational screening of the p16 gene (data not shown).
Loss of heterozygosity
Non-isotopic PCR-LOH analysis using the microsatellite
marker D105532 found no allelic loss/LOH in the PXA
tumour sample.
Immunohistochemistry
Formalin-fixed, paraffin-embedded specimens of the patient
were examined for p53 protein expression. Immunohisto-
chemical staining was performed using the streptavidin-biotin/
peroxidase method and DO7 monoclonal antibody (Dako,
Copenhagen, Denmark), as previously described by Wang et
al.7 No p53 protein expression was detected in the tumour
samples.
tumour were generally thick-walled and lacked endothelial
proliferation. Necrosis was seen only at the inner side towards
the cystic cavity. Serpiginous foci of tumour necrosis with
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Discussion
A literature survey covering 46 papers yielded 88 different
cases of PXA that fulfilled the histological criteria of Kepes et
al.1,8 In the literature review, the male:female sex ratio for PXA
was 53:47 and the average age of patients was 17.5 years, with
a range from 3 to 66 years.1,8–12 The most common presenting
symptom was seizure, found in 74% of patients. This could
have been due to the irritative effect of the tumour, which was
typically situated superficially near the cortex and attached to
the leptomeninges. Other presenting symptoms were raised
ICP, headache and paraparesis. However, there was a rare
report of a 46-year-old woman who had massive left temporal
lobe intraparenchymal and diffuse subarachnoid haemorrhage
on brain CT.13 The sites usually involved were the temporal
lobe (61%), parietal lobe (11%), frontal lobe (9%), occipital lobe
(5%), basal ganglia (6%) and 1% each for the cerebellum and the
thoracic spine.8 Imaging usually showed a superficially located,
often cystic tumour with a solid, enhancing nodule and little
perifocal oedema. Evidence of meningeal infiltration could be
a strong diagnostic point because meningeal infiltration was
much less common in other gliomas, with the exception of the
pilocytic astrocytoma.14
Preoperative differentiation of PXA from other supra-
tentorial tumours can be difficult and CT might show variable
appearances.9 The differential diagnosis of the lesion includes
meningioma, cystic and solid astrocytoma, oligodendroglioma
and solitary cerebral metastasis. Carotid angiography usually
demonstrates an avascular mass.10 In our patient, CT showed
a multiloculated, ring-enhancing, low-density lesion in the
left temporal lobe associated with surrounding oedema
(Figure 1).
The histological features of PXA can be summarized
as follows: strikingly pleomorphic tumour cells, little evidence
of mitosis, focal cystic change but no necrosis, and the
presence of a rich pericellular reticulin network. Cytoplasm
immunohistochemical staining for GFAP, a marker for
astrocytes, suggests astrocytic origin.1 The presence of basal
laminae demonstrated by electron microscopy specifically
implicates the subpial fibrous astrocytes as the progenitor cell
of the tumour.1–3,9 The characteristic features of PXA such as
paucity of mitoses, no necrosis and no endothelial proliferation
can be regarded as indices of slow growth. The presence of
mitotic figures and necrosis are uncommon in PXA, and their
presence is interpreted as indication of malignant
transformation and poor prognosis.2,3,8,15 Nonetheless, cases
of PXA with the presence of foci of necrosis and mitosis have
been reported as atypical PXA, and opinion has been expressed
that their presence should not lead one to exclude the diagnosis
of PXA.16,17 Necrosis, though present in our PXA case, was
confined to the lining of the cystic cavity. Serpiginous tumour
necrosis, with pseudopallisading of tumour cells and
glomeruloid endothelial cell proliferation, considered typical
of glioblastoma, was not seen. Furthermore, the tumour
displayed a well-defined outer margin without infiltrative
growth. Additionally, the presence of diastase-resistant, PAS-
positive granules and rich pericellular reticulin network
favoured a diagnosis of PXA.
Complete gross resection of the tumour is the best
therapeutic option. Our patient underwent incomplete excision
of the tumour due to technical difficulty; because of this and
the high mitotic index histologically, he underwent
radiotherapy. There is no reported obvious difference in the
outcomes of patients treated by surgery alone and those treated
by surgery and radiotherapy.18 Our patient recovered 6 weeks
after radiotherapy commenced. The value of radiotherapy,
therefore, remains unclear, and the inclination is to restrict
postoperative radiotherapy to cases of recurrent PXA that
histologically present as a malignant glioma.17 The role of
chemotherapy is unclear.15–19
Davies et al reviewed 22 patients with PXA considered to
have had total surgical removal of their tumours.10 Of the 22,
Figure 3. Agarose gel electrophoresis showing the results of single-
strand conformation polymorphism analysis of the p53 gene
mutation in the pleomorphic xanthoastrocytoma (PXA). N = DNA
from corresponding normal tissue; T1 = PXA tissue DNA; T2 =
juvenile pilocytic astrocytoma tumour tissue DNA. Lane T2 (no
mutation of p53 in the juvenile pilocytic astrocytoma specimen)
gave the same bands as the control wild-type p53 DNA in lane N. The
arrowheads show an extra band in the tumour sample.
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15 were alive and free of recurrence at a mean of 10.6 years
(1–18 years) after surgery and seven had recurrences at a mean
of 5 years (4 months to 15 years) after surgery. Of these
recurrences, five patients showed histopathological evidence
of glioblastoma and one showed malignant astrocytoma
identified in a portion of the tumour at the time of the initial
resection. The remaining patient had necrotic areas in the
original tumour, and therefore, it might have been truly
malignant at that time. However, where recurrence had shown
similar findings to the initial pathology, the patients had done
well following repeat surgery.1,11,15 Although in our case the
high mitotic index suggested the possibility of an aggressive
course, the patient made good clinical improvement and
remained well until the last follow-up, 2 years after the
operation. The longest documented case of PXA survival so
far is 18 years.20
The World Health Organization defines PXA as an
astrocytic tumour with a mixture of pleomorphic tumour
cells.21,22 A number of molecular abnormalities are associated
with astrocytoma, and recent studies suggest that most of
these abnormalities converge on cell cycle regulation, which
includes the p534,23 and p16 genes.24 Another molecular marker
is LOH for chromosome 10.25 While the molecular genetic
basis of diffuse astrocytomas has been studied extensively,
only a small number of PXA cases have been analyzed in detail.
Recently, the presence of p53 gene mutation in PXA was reported
by Paulus et al26 and Giannini et al.27 Prior studies showed that
p53 mutations may occur in up to 25% of PXAs, suggesting
that PXA may have an aetiology similar to diffuse astrocytoma
rather than pilocytic astrocytoma.27 Our molecular genetic
findings showed the deletion of a 4-bp stretch of nucleotides
(CTGG) at codons 273 and 274 in exon 8; on subsequent
immunostaining, no p53 protein expression was noted. The
discrepancy between patients with p53 mutation without its
protein expression, deletions or insertions of base pairs may
result in frameshift mutations. These patients may have
truncated p53 protein that might not be detected immuno-
histochemically.23 Severely truncated p53 protein might lose
its antibody binding site or have an altered epitope structure,
resulting in immunonegativity for p53.
In addition, we found no suggestion of any rearrangement
or mutation in exons 1 and 2 of the p16 gene. Analysis of the
PXA specimen using the D105532 microsatellite marker did
not show any LOH compared to a normal sample. We speculate
that there is no significant tumour suppressor gene involved
in the region of 10q23 in our PXA case. Paulus et al also
reported that LOH for chromosome 10q was not found in
PXA.26 The mutation of the p16 gene was not involved in our
case and no current English literature supports this finding.
We postulate that the p16 gene and LOH on chromosome 10
did not contribute to tumorigenesis of PXA in this patient.
Conclusions
PXA is a distinct and specific type of astrocytoma that can
be readily diagnosed on the basis of both clinical and
morphological findings. Complete gross resection of tumour,
if possible, is the best therapeutic option for PXA at present
and, when necessary, repeat surgery for recurrence. When the
recurrent tumour is histologically similar to the originally
benign tumour, long-term survival is possible. However, PXA
is also capable of malignant change to glioblastoma, for which
the prognosis is unfavourable. Long-term follow-up, even
after total removal of the tumour, is essential in all PXA
patients. In our patient, mutation of the p53 gene was identified,
and this finding agrees with the findings of Giannini et al,27
suggesting that the p53 mutation appears to be a genetic event
in the tumorigenesis of PXA. Therefore, we conclude that p53
mutations may contribute to PXA carcinogenesis in the
Malaysian population.
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